Skin Fibrosis Treatment Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-03-27　·　156 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 796 Mn
2033 年預估規模: USD 1,267 Mn
年複合成長率 CAGR: 6.9%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-03-27頁數 156報告編號 CMI5255

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Skin Fibrosis Treatment Market, By Drug Type (Corticosteroids, Antifibrotic, Immunotherapy Drugs, Other(Immunosuppressant)), By Route of Administration (Oral, Parenteral, Other(Topical)), By Application (Localized forms of scleroderma, Eosinophilic fasciitis, Scleromyxedema (papular mucinosis), and Scleredema), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

報告摘要

Skin fibrosis generally occurs in patients who suffer from eosinophilia-myalgia syndrome, scleromyxedema (papular mucinosis) and scleredema. Fibrosis frequently develops as a result of continuous chemical exposure or trauma that causes epidermal or dermal harm. It is characterized by an increase of fibrous connective tissues in the dermis or subcutis and frequently goes hand in hand with persistent inflammation. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. An increase in fibrous connective tissues in the dermis is one of its defining features. Systemic sclerosis (SSc also known as scleroderma), which also causes fibrosis in a number of other organs, is characterized by the primary symptom of skin fibrosis. Although, this fibrosis cannot be reversed, it can be treated to some extent using currently available drugs. Dermal fibrosis, which results from a pathologic reaction to wound healing, is excessive skin scarring. Scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis are only a few of the many fibrotic skin illnesses that exist. Market Dynamics The rise in recent advances in treatment for the skin fibrosis is expected to drive the global skin fibrosis treatment market growth over the forecast period. For instance, in December 2017, according to the data published by the Springer Nature, the new treatment strategy has shown promising results in the treatment of skin fibrosis. The treatment involves the molecular targeting therapy with monoclonal antibody. The positive clinical outcomes had been reported in rituximab (an anti-CD20 antibody) and the tocilizumab (an anti-interleukin-6 (IL-6) receptor antibody). Key features of the study • This report provides an in-depth analysis of the global skin fibrosis treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global skin fibrosis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global skin fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin fibrosis treatment market Skin Fibrosis Treatment Market Segmentation • By Drug Type Insights (Revenue, USD Mn, 2020 - 2033) o Corticosteroids o Antifibrotic Drugs o Immunotherapy Drugs o Other (Immunosuppressant) • By Route of Administration Insights (Revenue, USD Mn, 2020 - 2033) o Oral o Parenteral o Other (Topical) • By Application Insights (Revenue, USD Mn, 2020 - 2033) o Localized forms of scleroderma o Eosinophilic fasciitis o Scleromyxedema (papular mucinosis) o Scleredema • By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033) o Hospital Pharmacies o Retail Pharmacies o Online Pharmacies • By Region Insights (Revenue, USD Mn, 2020 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East & Africa  GCC Countries  Israel  Rest of Middle East & Africa • Key Players in the Skin Fibrosis Treatment Market o Pharmaxis o Jubilant Cadista o Horizon Pharma USA o Pfizer, Sanofi o Hoffmann-La Roche o Boehringer Ingelheim o Bristol-Myers Squibb Company

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Market Snapshot, By Drug Type  Market Snapshot, By Route of Administration  Market Snapshot, By Application  Market Snapshot, By Distribution Channel  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Recent Developments o Acquisitions and Partnerships Scenario o Technology Overview o Regulatory Scenario o Pricing Analysis o PEST Analysis 4. Global Skin Fibrosis Treatment Market, By Drug Type, 2020 – 2033, (USD Mn) o Overview  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2020 – 2033  Segment Trends o Corticosteroids  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Antifibrotic Drugs  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Immunotherapy Drugs  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Other (Immunosuppressant)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) 5. Global Skin Fibrosis Treatment Market, By Route of Administration, 2020 – 2033, (USD Mn) o Overview  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2020 – 2033  Segment Trends o Oral  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Parenteral  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Other (Topical)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) 6. Global Skin Fibrosis Treatment Market, By Application, 2020 – 2033, (USD Mn) o Overview  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2020 – 2033  Segment Trends o Localized forms of scleroderma  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Eosinophilic fasciitis  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Scleromyxedema (papular mucinosis)  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Scleredema  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) 7. Global Skin Fibrosis Treatment Market, By Distribution Channel, 2020 – 2033, (USD Mn) o Overview  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2020 – 2033  Segment Trends o Hospital Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Retail Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) o Online Pharmacies  Overview  Market Size and Forecast, and Y-o-Y Growth, 2020–2033, (USD Mn) 8. Global Skin Fibrosis Treatment Market, By Region, 2020 – 2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2026 and 2033 (%)  Y-o-Y Growth Analysis, For Regions, 2020–2033  Regional Trends o North America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2033, (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2033, (USD Mn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2033, (USD Mn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2033, (USD Mn) o GCC o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)  Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 – 2033, (USD Mn) o North Africa o Central Africa o South Africa 9. Competitive Landscape o Pharmaxis  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Jubilant Cadista  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Horizon Pharma USA  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Pfizer  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Sanofi  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o F. Hoffmann-La Roche  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Boehringer Ingelheim  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies o Bristol-Myers Squibb Company  Company Highlights  Product Portfolio  Key Highlights  Financial Performance  Market Strategies 10. Section o Research Methodology o About Us

提及公司

PharmaxisJubilant CadistaHorizon Pharma USAPfizer, SanofiHoffmann-La RocheBoehringer IngelheimBristol-Myers Squibb Company

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們